Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Depreciation and Depletion (2016 - 2025)

Historic Depreciation and Depletion for Editas Medicine (EDIT) over the last 11 years, with Q3 2025 value amounting to $721000.0.

  • Editas Medicine's Depreciation and Depletion fell 5490.93% to $721000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $5.9 million, marking a year-over-year decrease of 129.85%. This contributed to the annual value of $5.8 million for FY2024, which is 477.05% down from last year.
  • Editas Medicine's Depreciation and Depletion amounted to $721000.0 in Q3 2025, which was down 5490.93% from $1.8 million recorded in Q2 2025.
  • Editas Medicine's 5-year Depreciation and Depletion high stood at $1.9 million for Q1 2025, and its period low was $721000.0 during Q3 2025.
  • Over the past 5 years, Editas Medicine's median Depreciation and Depletion value was $1.5 million (recorded in 2023), while the average stood at $1.5 million.
  • In the last 5 years, Editas Medicine's Depreciation and Depletion skyrocketed by 4573.93% in 2021 and then crashed by 5490.93% in 2025.
  • Quarter analysis of 5 years shows Editas Medicine's Depreciation and Depletion stood at $1.6 million in 2021, then grew by 1.22% to $1.6 million in 2022, then fell by 4.76% to $1.5 million in 2023, then decreased by 8.06% to $1.4 million in 2024, then plummeted by 47.79% to $721000.0 in 2025.
  • Its Depreciation and Depletion was $721000.0 in Q3 2025, compared to $1.8 million in Q2 2025 and $1.9 million in Q1 2025.